A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types

Oncology Reports

Volumn 24, Issue 2, 2010, Pages 489-494

  Wan, Ying Wooi ^a   Qian, Yong ^b   Rathnagiriswaran, Shruti ^a   Castranova, Vincent ^b   Guo, Nancy Lan ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Breast cancer; Colon cancer; Lung adenocarcinoma; Ovarian cancer; Prognostic gene signature

Indexed keywords

ADRIAMYCINONE; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROTEIN P53; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; PHARMACOLOGICAL BIOMARKER; TAMOXIFEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER TISSUE; CARCINOGENESIS; COLON TUMOR; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CLASSIFICATION; EVALUATION STUDY; GENETICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; NEOPLASMS; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME; VALIDATION STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; METHOTREXATE; NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954355878     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000883     Document Type: Article

References (18)

1. Bergfeldt K, Rydh B, Granath F, Gronberg H, Thalib L, Adami HO and Hall P: Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet 360: 891-894, 2002.
2. Wooster R and Weber BL: Breast and ovarian cancer. N Engl J Med 348: 2339-2347, 2003.
3. Ma Y, Qian Y, Wei L, et al: Population-based molecular prognosis of breast cancer by transcriptional profiling. Clin Cancer Res 13: 2014-2022, 2007.
4. Rathnagiriswaran S, Wan YW, Abraham J, Castranova V, Qian Y and Guo NL: A population-based gene signature is predictive of breast cancer survival and chemoresponse. Int J Oncol 36: 607-616, 2010.
5. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357, 2006.
6. Barrier A, Boelle PY, Roser F, et al: Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24: 4685-4691, 2006.
7. Barrier A, Roser F, Boelle PY, et al: Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26: 2642-2648, 2006.
8. Shedden K, Taylor JM, Enkemann SA, et al: Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827, 2008.
9. Everitt B and Hothorn T: A Handbook of Statistical Analyses Using R. Chapman & Hall/CRC, Boca Raton, FL, 2006.
10. Liu R, Wang X, Chen GY, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226, 2007.
11. Chi JT, Wang Z, Nuyten DS, et al: Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: E47, 2006.
12. Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524, 2005.
13. Cibas E and Ducatman B: Cytology: diagnostic principles and clinical correlates. 2nd edition. Cibas E and Ducatman B (eds). W.B. Saunders, Edinburgh, 2006.
14. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
15. Van de Vijver MJ, He YD, van't Veer LJ, et al: A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
16. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
17. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102: 3738-3743, 2005.
18. Massague J: Sorting out breast-cancer gene signatures. N Engl J Med 356: 294-297, 2007.